Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

Results from the MARVEL 2 (Micra Atrial Tracking Using A Ventricular accELerometer) study shows that an investigational set of algorithms in the Medtronic Micra Transcatheter Pacing System (TPS) significantly improves synchrony and cardiac function in patients with atrioventricular (AV) block. This is an impaired electrical conduction between the chambers of the heart.
News | Pacemakers | November 15, 2019

(February 2020 update — the results of this trial led to the FDA clearnace of the Micra AV device in January 2020...

The ClotTriever system (Inari Medical), a mechanical thrombectomy system FDA 510(k) cleared for the nonsurgical removal of soft thrombi and emboli from peripheral blood vessels.  #VIVA19 #VIVA2019

The ClotTriever system (Inari Medical), a mechanical thrombectomy system FDA 510(k) cleared for the nonsurgical removal of soft thrombi and emboli from peripheral blood vessels. 

 

News | Deep Vein Thrombosis (DVT) | November 14, 2019

November 7, 2019 — The ClotTriever Outcomes (CLOUT) Registry is evaluating real-world patient outcomes following...

News | Peripheral Artery Disease (PAD) | November 14, 2019

November 7, 2019 — Ultrasoundplasty before angioplasty for below-the-knee lesions (BTK) lesions may improve clinical...

 doctor heart failure patient from CorAssist
News | AHA | November 14, 2019

November 14, 2019 — More than a million Americans face a doubling in their risk of death during or while recovering...

News | Peripheral Artery Disease (PAD) | November 14, 2019

November 14, 2019 — There were positive results in the TANGO Trial is a phase 2, dose escalation, double-blinded...

The LimFlow procedure permanently bypasses unreconstructable arteries and leverages healthier veins as a conduit to create new routes to perfuse tissue in the foot.  #VIVA #VIVA19 #VIVA2019

The LimFlow procedure permanently bypasses unreconstructable arteries and leverages healthier veins as a conduit to create new routes to perfuse tissue in the foot. 

News | Peripheral Artery Disease (PAD) | November 14, 2019

November 14, 2019 — Results were positive for the multicenter PROMISE I Trial represents the first human use in the...

 Cholesterol test prep blood draw needle stick from American Heart Association
News | AHA | November 14, 2019

November 14, 2019 — A large majority of patients with atherosclerotic cardiovascular disease (ASCVD) in the...

The Endospan Ltd. Nexus aortic arch stent graft is a CE mark–approved, off-the-shelf system for endovascular treatment of pathologies extending or involving the aortic arch.  #VIVA19 #VIVA2019

The Endospan Ltd. Nexus aortic arch stent graft is a CE mark–approved, off-the-shelf system for endovascular treatment of pathologies extending or involving the aortic arch. 

News | Endovascular Aortic Repair | November 11, 2019

November 7, 2019 — The Endospan Ltd. Nexus aortic arch stent graft is a CE mark–approved, off-the-shelf system for...

The repuncturable Supera vascular mimetic peripheral stent system from Abbott Vascular was shown to manage bulky, heavily calcified CFA disease due to its extreme crush resistance in the VMI-CFA study. #VIVA #VIVA19 #VIVA2019

The repuncturable Supera vascular mimetic peripheral stent system from Abbott Vascular was shown to manage bulky, heavily calcified CFA disease due to its extreme crush resistance in the VMI-CFA study.

News | Stents Carotid | November 11, 2019

November 11, 2019 — Although common femoral artery (CFA) endarterectomy is still considered the gold standard...

 Indigo System CAT RX Aspiration Catheter and Penumbra Engine
News | November 08, 2019

November 8, 2019 — Penumbra Inc. announced that the EXTRACT-PE trial...

 Bioresorbable stent Abbott Absorb stent
News | November 08, 2019

November 8, 2019 — The Absorb bioresorbable stent (BVS) demonstrated good patency and clinical outcomes in patients...

News | Stents Bioresorbable | November 07, 2019

November 7, 2019 — Although the Abbott Absorb fully bioresorbable drug-eluting stent (DES) was...

The final, long-term, patient-level data for the Cook Medical Zilver PTX drug-eluting stent (DES) were evaluated to determine if there is an increased mortality risk due to paclitaxel, but was no difference was seen in the five-year mortality rates compared to control patients. #VIVA19 #VIVA #VIVA2019

The final, long-term, patient-level data for the Cook Medical Zilver PTX drug-eluting stent (DES) were evaluated to determine if there is an increased mortality risk due to paclitaxel, but was no difference was seen in the five-year mortality rates compared to control patients.

 

Feature | Stents Peripheral | November 06, 2019 | Dave Fornell, Editor

November 6, 2019 – The final, long-term, patient-level data for the Cook Medical Zilver PTX drug-eluting stent (DES...

The Selution SLR, MedAlliance’s novel sirolimus-eluting balloon, #VIVA2019 #VIVA #VIVA19
News | Drug-Eluting Balloons | November 06, 2019

November 6, 2019 – Positive, two-year data from the first-in-human study of Selution SLR, MedAlliance’s novel...

Eluvia and Ranger PAD devices from Boston Scientific. #VIVA19 #VIVA2019 #VIVA
News | Peripheral Artery Disease (PAD) | November 06, 2019

November 6, 2019 – Boston Scientific announced positive data for two of its devices within the peripheral drug-...

Overlay Init